Home/Ray Therapeutics/Chris Whitmore, CPA
CW

Chris Whitmore, CPA

Chief Financial Officer

Ray Therapeutics

Ray Therapeutics Pipeline

DrugIndicationPhase
RTx-015Retinitis PigmentosaPhase 1
RTx-021Stargardt’s DiseaseDiscovery